All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Currently, the standard of care for healthy patients with Newly Diagnosed Multiple Myeloma (NDMM) is treatment with high-dose melphalan (HDM) followed by Autologous Stem-Cell Transplantation (ASCT). However, this is not curative and a prolonged course of maintenance therapy is required for long-term control. Lenalidomide treatment has been found to be a suitable agent as it has a tolerable safety profile and significantly prolongs Progression Free Survival (PFS). However, few of the Randomized Controlled Trials (RCTs) were powered to assess Overall Survival (OS). Therefore, in order to further evaluate the available data, a meta-analysis of three RCTs to assess the efficacy of lenalidomide maintenance therapy after ASCT (in NDMM), was conducted by Philip McCarthy from the Roswell Park Cancer Institute, Buffalo, New York, and colleagues. Their findings were published in Journal of Clinical Oncology in July 2017.
The three RCTs chosen for analysis were the Cancer and Leukemia Group B 100104, the Gruppo Italiano Malattie Ematologiche dell’Adulto RV-MM-PI-209, and the IFM (Intergroupe Francophone du Myélome) 2005-02. The number of patients (pts) included in the study was 1,208; lenalidomide group (n=605) and placebo or observational group (n=603). The primary endpoint for the meta-analysis was Overall Survival (OS).
This meta-analysis confirmed significant PFS and OS benefit with lenalidomide maintenance after ASCT therapy in patients with NDMM, compared with patients receiving the placebo or in the observation group. Interestingly, the PFS benefit was lower in patients over the age of 60 and for females. Limitations of this analysis include the small number of trials included in the study and the differences between studies, such as length of maintenance therapy.
Purpose: Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods: The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results: Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion: This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox